Route 92 Medical develops neurovascular intervention technologies for acute ischemic stroke, notably the HiPoint Reperfusion System and its Monopoint approach to improve endovascular thrombectomy efficiency. The company completed the 250-patient SUMMIT MAX randomized trial, reporting strong safety and a high first pass effect rate. After submitting those results, the HiPoint Reperfusion System received FDA clearance in May 2025 for neurothrombectomy procedures. Route 92 has reported rapid growth in product adoption and an expanding commercial organization. With $50 million in new growth financing, the company intends to accelerate global commercial expansion, build clinical evidence for broader adoption, and continue investing in product innovation. Investors cited robust manufacturing capacity and a well-differentiated product portfolio as reasons for supporting the company’s next phase of growth.

Total raised

$192M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2026